Cedars-Sinai https://www.cedars-sinai.org has established their new Artificial Intelligence in Medicine (AIM) Program to explore how AI can be applied to help discover major modern medical breakthroughs.
The program’s current focus is on cardiac imaging, sudden cardiac arrest, COVID-19, and clinical genetics and has recently used algorithms to identify patients at risk for heart attacks.
Sumeet Chugh, MD, Associate Director of the Smidt Heart Institute and an expert in sudden cardiac arrest, has long relied on technology and population-wide data to help demystify who might be susceptible to the usually fatal heart rhythm disturbance.
“Through the use of applied AI, we can solve existing gaps in mechanisms, diagnostics, and therapeutics of major human disease conditions which afflict large populations. The future of medicine lies in decoding enormous amounts of phenotypic and genotypic patient data,” reports, Paul Noble, MD, Professor of Medicine and Chair of the Department of Medicine who created the new division.
In conjunction with AIM, Cedars-Sinai has developed several key programs in which AI is being increasingly deployed. Jason H. Moore, PhD, was named Founding Chair of the Department of Computational Biomedicine which is a systemwide program committed to advancing medical discoveries by interfacing data sciences with clinical information.
Also, Cedars-Sinai’s Enterprise Data Intelligence team led by Mike Thompson uses AI tools to facilitate patient care at the hospital level which is a particularly valuable resource that enabled outstanding care during the pandemic.
Dr. Chugh said, AIM has a multidisciplinary mandate. With its current focus on cardiac imaging, sudden cardiac arrest, COVID-19 and clinical genetics, Dr. Chugh hopes that division members will tackle a broad range of medical, surgical, and public health problems. He said, “By using a disease-based approach, AIM will enable cross-disciplinary connections between clinicians, scientists, and trainees at Cedars-Sinai at multiple levels.”